US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bayer A.G.

7.59

+0.06900.92%

Post-market: 7.590.00000.00%16:11 EDT

Volume:837.03K

Turnover:6.31M

Market Cap:29.83B

PE:-8.46

High:7.60

Open:7.48

Low:7.46

Close:7.52

Loading ...

Overview Company News Filings

PCRX Stock Soars on Exparel Patent Settlement With Generic Players

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

Bayer Asks Supreme Court to Review Roundup Case

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication

FMC, Bayer collaborate to bring Isoflex to European markets

Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug

Elliott gauged investor interest in Bayer’s consumer health business, FT says

Is Bayer (BAYRY) Stock Outpacing Its Medical Peers This Year?

Nvidia, Palantir, Tesla, MicroStrategy, Bayer, James Hardie, AZEK: Stocks to watch today

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

8 key drug patents expiring soon — and what it means for the market

Bayer Ordered to Pay $2.1 Billion After Losing Roundup Weedkiller Case

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BAYRY/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":7.59,"timestamp":1749240000000,"preClose":7.521,"halted":0,"volume":837032,"hourTrading":{"tag":"盘后","latestPrice":7.59,"preClose":7.59,"latestTime":"16:11 EDT","volume":549,"amount":4166.91,"timestamp":1749240699960},"delay":15,"floatShares":3929259738,"shares":3929696328,"eps":-0.897103,"marketStatus":"Market Closed","change":0.069,"latestTime":"06-06 16:00:00 EDT Delay","open":7.48,"high":7.6,"low":7.46,"amount":6313842.425099995,"amplitude":0.018615,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.897103,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":0.25,"exchange":"OTCQX","adjPreClose":7.521,"volumeRatio":1.614050378597038},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"2.55%","roe":"-9.49%","lyrEps":-0.672343,"volumeRatio":1.614050378597038,"shares":3929696328,"dividePrice":0.031351,"high":7.6,"amplitude":0.018615,"preClose":7.521,"low":7.46,"week52Low":4.79,"pbRate":"0.81","psRate":"0.56","week52High":8.58,"institutionHeld":0,"latestPrice":7.59,"eps":-0.897103,"divideRate":0.004131,"volume":837032,"delay":15,"ttmEps":-0.897103,"open":7.48,"prevYearClose":4.88,"prevWeekClose":7.07,"prevMonthClose":7.07,"prevQuarterClose":6.02,"fiveDayClose":7.07,"twentyDayClose":6.64,"sixtyDayClose":6.26},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526846907","title":"PCRX Stock Soars on Exparel Patent Settlement With Generic Players","url":"https://stock-news.laohu8.com/highlight/detail?id=2526846907","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526846907?lang=en_us&edition=fundamental","pubTime":"2025-04-08 23:29","pubTimestamp":1744126140,"startTime":"0","endTime":"0","summary":"Shares of Pacira BioSciences PCRX are rising today after the company announced that it has entered into a settlement agreement with Fresenius, Jiangsu Hengrui Pharmaceuticals and eVenus Pharmaceuticals Laboratories, related to patents for Exparel .Following the settlement, which resolves the patent litigation brought by Pacira BioSciences against the companies, Consent Judgments will be filed in multiple courts, preventing Fresenius, like the others, from marketing generic bupivacaine liposome injectable suspension before the relevant patents expire, except as outlined in the agreement.Exparel is PCRX’s flagship pain-management product,which was initially launched in 2012. The drug is indicated for postsurgical local analgesia in patients aged six years and older. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.Year to date, shares of Pacira Bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pcrx-stock-soars-exparel-patent-152900546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","PCRX","DVAX","BK4139","BK4007","BAYRY"],"gpt_icon":0},{"id":"2526846182","title":"RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2526846182","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526846182?lang=en_us&edition=fundamental","pubTime":"2025-04-08 23:21","pubTimestamp":1744125660,"startTime":"0","endTime":"0","summary":"Shares of Rhythm Pharmaceuticals RYTM rallied 17.1% on Monday after the company announced that it has met the primary endpoint in a late-stage study of its candidate, setmelanotide, for treating acquired hypothalamic obesity.RYTM’s setmelanotide is an MC4R agonist.Per the data readout, the phase III TRANSCENDstudy met its primary endpoint with a statistically significant and clinically meaningful reduction in body mass index  with setmelanotide in adult and pediatric patients compared to placebo. It was observed that all patients with acquired hypothalamic obesity who underwent setmelanotide therapy experienced an average BMI reduction of 16.5% over 52 weeks, whereas those on placebo saw a 3.3% increase.Please note that setmelanotide is already approved as Imcivree in the United States and EU for chronic weight management in adult and pediatric patients aged two years and older with certain genetic conditions. The eligible patient population includes those with monogenic or syndromic o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rytm-stock-rises-17-meeting-152100157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DVAX","BAYRY","ADMA","BK4585","BK4139","BK4007","BK4157","BK4588","BMI","RYTM"],"gpt_icon":0},{"id":"2525024795","title":"Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2525024795","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525024795?lang=en_us&edition=fundamental","pubTime":"2025-04-08 01:01","pubTimestamp":1744045260,"startTime":"0","endTime":"0","summary":"1701 GMT - Bayer's filing to review a lower court's decision on a case alleging the company's Roundup product caused cancer is the next step forward in the litigation, Morgan Stanley analysts say. The German pharmaceutical company argues that the \"failure-to-warn\" claims, on which all glyphosate cases are based, are preempted by the Federal Insecticide, Fungicide, and Rodenticide Act's labeling rules, the analyst says. The Supreme Court could potentially decide on whether or not to take the case in the second quarter, with a potential final decision by end 2025 or in the first half of 2026, they say. Shares fall 1.3% to 19.83 euros. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU0098860793.USD","BK4127","LU1162221912.USD","LU2028103732.USD","BAYRY","LU0971096721.USD","LU1363072403.SGD","LU0314104364.USD","LU2111349929.HKD","LU1548497426.USD","LU2347655156.SGD","BK4581","FORD","LU0795875086.SGD","IE00BZ1G4Q59.USD","LU1989772840.SGD","LU0106831901.USD","LU1732799900.SGD","LU2357305700.SGD","LU1074936037.SGD","LU0158827781.USD","BK4007","IE00BKVL7J92.USD","LU2089283258.USD","LU1989772923.USD","LU2023251221.USD","LU0225283273.USD","BK4516","BK4504","LU0795875169.SGD","LU1668664300.SGD","LU0912757837.SGD","BK4585","BK4145","LU2089284900.SGD","LU0006306889.USD","LU1720051108.HKD","BK4202","LU0320765646.SGD","LU0158827948.USD","LU1732800096.USD","LU1720051017.SGD","LU0106261372.USD","LU0267386448.USD","BK4588","LU2271345857.HKD","LU2133065610.SGD"],"gpt_icon":0},{"id":"2525170734","title":"Bayer Asks Supreme Court to Review Roundup Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2525170734","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525170734?lang=en_us&edition=fundamental","pubTime":"2025-04-05 03:14","pubTimestamp":1743794040,"startTime":"0","endTime":"0","summary":"Bayer filed for the Supreme Court to review a lower court's decision on a case alleging the company's Roundup product caused cancer.Bayer said Friday it had filed a petition for a writ of certiorari with the Supreme Court, arguing that a split among federal circuit courts in the Roundup litigation warrants review and resolution by the top court.In 2023, a Missouri Circuit Court returned a verdict in favor of John Durnell, who alleged the weed control product Roundup caused non-Hodgkin's lymphoma. Bayer bought the agrochemical company Monsanto, which makes Roundup, in 2018.The Missouri court's verdict rests on the claim that state law requires companies to warn if their products are carcinogenic, Bayer said.Different courts have reached different conclusions, which is why Bayer is arguing the Supreme Court needs to rule on the issue.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2524326247","title":"DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2524326247","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524326247?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:32","pubTimestamp":1743687120,"startTime":"0","endTime":"0","summary":"Shares of Denali Therapeutics DNLI gained 11.8% on Wednesday after the company announced that it has initiated a rolling submission of a biologics license application  for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome . The same has also been received by the Center for Drug Evaluation and Research of the FDA.DNLI reported ongoing collaborative and productive engagement with CDER, aligning with the same on the content of the BLA data package, including the use of CSF HS as a surrogate endpoint for accelerated approval and the path to full approval.Denali expects to complete its BLA submission by mid-May 2025 and is preparing for a potential U.S. commercial launch in late 2025 or early 2026. Tividenofusp alfa, an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase  replacement therapy, enjoys the FDA’s Fast Track and Breakthrough Therapy designations in the United States for MPS II.In the EU, the candidate enjoys the Priority Medicines designation for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dnli-begins-rolling-bla-submission-133200898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1559883803.SGD","LU0566484027.USD","BAYRY","DNLI","DVAX","BK4535","BK4548","BK4532","BK4007","BK4139"],"gpt_icon":1},{"id":"2524419264","title":"NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2524419264","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524419264?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:08","pubTimestamp":1743685680,"startTime":"0","endTime":"0","summary":"Nurix TherapeuticsNRIX shares rose 8.7% on Wednesday after the company announced that Sanofi SNY has in-licensed exclusive rights to an undisclosed Nurix program aimed at a previously untreatable transcription factor for autoimmune diseases. This undisclosed target plays a key role in regulating inflammation and is separate from the previously revealed STAT6 degrader program, signed between the companies in 2019. The stock is gaining further in the pre-market hours on Thursday.Nurix and Sanofi first established a strategic collaboration in 2019 to develop and commercialize a portfolio of targeted protein degradation therapies for patients with complex diseases across various therapeutic areas. The partnership utilizes NRIX’s proprietary DEL-AI discovery platform to discover small molecules that promote the degradation of three initially designated drug targets. In 2021, Sanofi exercised its option to expand the number of targets from three to five.The latest update further expands the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrix-stock-sny-licenses-rights-130800564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNY","BK4532","BK4588","BK4585","LU1559883803.SGD","NRIX","LU0566484027.USD","BK4139","BAYRY","IE00BFXG1179.USD","BK4007"],"gpt_icon":1},{"id":"2524581497","title":"APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2524581497","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524581497?lang=en_us&edition=fundamental","pubTime":"2025-04-02 21:11","pubTimestamp":1743599460,"startTime":"0","endTime":"0","summary":"A filing accepted under the regulatory body’s Priority Review pathway reduces the review period to six months from the standard 10 months. This status is awarded to marketing applications for medicines intended to treat serious conditions and that, if approved, would offer a substantial improvement in safety, effectiveness, prevention, or diagnosis of such conditions.A final decision from the FDA is expected on July 28, 2025.Please note that Empaveli is approved in the United States for the treatment of paroxysmal nocturnal hemoglobinuria . The drug is also approved in Europe under the brand name Aspaveli for the same indication.Year to date, shares of Apellis have plunged 28.9% against theindustry’s 2.4% growth.In the VALIANT study, Empaveli was overall well-tolerated with a consistent safety profile. Adverse events were mostly mild to moderate in severity.Novartis recently announced that the FDA has approved Fabhalta for a third indication, C3G, to reduce proteinuria.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apls-empaveli-snda-2-rare-131100793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVS","LU1093756168.USD","CORT","LU0070302665.USD","BK4532","APLS","IE00BJJMRZ35.SGD","LU0320765489.SGD","LU0208291251.USD","LU0566484027.USD","LU1093756325.SGD","BK4578","IE0002141913.USD","BK4588","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0211331839.USD","IE0009355771.USD","LU1559883803.SGD","BK4007","BAYRY","BK4139","IE00B4R5TH58.HKD","BK4585","BK4505"],"gpt_icon":0},{"id":"2524451039","title":"Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2524451039","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524451039?lang=en_us&edition=fundamental","pubTime":"2025-04-02 17:27","pubTimestamp":1743586020,"startTime":"0","endTime":"0","summary":"Tesla : The e-vehicle maker's quarterly delivery figures are expected early Wednesday. Shares shed about 1% ahead of the open. The stock has slid this year amid a consumer backlash to Elon Musk's political activities, and tariff uncertainty.Auto stocks: In Germany, shares of automotive supplier Continental  and BMW  both declined. In Asia, Hyundai  lost 1.2%. Ford , General Motors  and Jeep maker Stellantis  were little changed in U.S. premarket trading.Global pharma stocks: Danish Ozempic maker Novo Nordisk  fell more than 2%. Also under pressure: Germany's Bayer , France's Sanofi  and the U.K.'s GSK . Most U.S. drug makers were little changed ahead of the bell.Newsmax : Shares slid more than 30% premarket, continuing a rollercoaster first week of trading for the conservative TV outlet.Grifols : Private-equity firm Brookfield Asset Management  has reopened takeover talks with Grifols. The pharmaceutical company's shares jumped 14% in Madrid midday trading.This item is part of a Wall S","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GM","TSYW.SI","SNY","LU2756315664.SGD","BK4527","STLA","GSK.UK","LU0648001328.SGD","TSLA","BK4550","LU0648000940.SGD","BK4574","NMAX","NVO","LU1861220033.SGD","BK4533","BK4561","LU1064927863.SGD","LU1201861165.SGD","LU1720051108.HKD","LU1914381329.SGD","BK4007","SG9999015978.USD","SG9999015945.SGD","LU2750360641.GBP","BK4532","LU0820562030.AUD","BK4598","BK4612","BK4566","LU0211331839.USD","LU2357305700.SGD","LU1093756325.SGD","TSLL","LU1548497426.USD","LU1551013342.USD","LU0234570918.USD","LU0345769631.USD","LU0345770308.USD","F","BAYRY","LU0154236417.USD","LU1066053197.SGD","LU1066051225.USD","LU1839511570.USD","LU0820561909.HKD","GRFS","CTTAY","LU2108987350.USD","GSK"],"gpt_icon":1},{"id":"2524145956","title":"SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2524145956","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524145956?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:44","pubTimestamp":1743515040,"startTime":"0","endTime":"0","summary":"SanofiSNY and partner,Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia  as the first antithrombin-lowering  therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients  with hemophilia A or B with or without factor VIII or IX inhibitors in the United States.Hemophilia A and B are rare, lifelong congenital bleeding disorders that impair the blood's ability to clot, causing excessive bleeding and spontaneous joint bleeds. These can lead to joint damage, chronic pain, which takes a significant toll on the patients’ quality of life.This FDA approval is based on positive data from the phase III ATLAS studies of Qfitlia, which showed clinically significant bleed protection, as measured by annualized bleeding rates , in hemophilia patients with or without inhibitors.Year to date, SNY stock has gained 15% compared with the industry’s 3.4% growth.Further analysis in the open-label extension study, under the ATL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sny-gets-fda-nod-first-134400996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNY","BK4532","LU0566484027.USD","BK4211","ABR","BK4548","CORT","BK4588","IE00BFXG1179.USD","BK4007","LU1559883803.SGD","BK4585","UBCP","BK4110","ALNY","BAYRY","BK4139"],"gpt_icon":0},{"id":"2524917146","title":"AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2524917146","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524917146?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:31","pubTimestamp":1743514260,"startTime":"0","endTime":"0","summary":"AstraZenecaAZN announced that the FDA has approved its blockbuster drug, Imfinzi, for a bladder cancer indication in the United States.Imfinzi is approved in combination with gemcitabine and cisplatin as a neoadjuvant treatment for muscle-invasive bladder cancer , a type of bladder cancer that has spread into the muscle wall of the bladder. The regulatory filing for the drug was reviewed under the FDA’s Priority Review Pathway. This marks the first approval for Imfinzi for a bladder cancer indication.AstraZeneca’s Imfinzi, either as a monotherapy or in combination with chemotherapy, is presently approved for stage III non-small cell lung cancer, extensive-stage small cell lung cancer, locally advanced or metastatic biliary tract cancer and endometrial cancer that is mismatch repair deficient and in combination with Imjudo in unresectable hepatocellular carcinoma in some countries. The drug has also recently been approved for limited-stage small cell lung cancer in the United States and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazenecas-imfinzi-gets-fda-nod-133100339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","LU2462157665.USD","LU0109394709.USD","AZN","BK4568","LU2417539215.USD","BK4588","LU0320765992.SGD","LU0566484027.USD","DVAX","CHMP","BK4007","CORT","LU2236285917.USD","LU1559883803.SGD","BK4585","BK4139","LU2456880835.USD","LU1829250122.USD","BAYRY","BK4087","BK4532"],"gpt_icon":0},{"id":"2524977781","title":"FMC, Bayer collaborate to bring Isoflex to European markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2524977781","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524977781?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:36","pubTimestamp":1743453393,"startTime":"0","endTime":"0","summary":"FMC (FMC) announced an agreement with Bayer (BAYRY) to commercialize products containing Isoflex active in the European Union and Great Britain. Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fmc-bayer-collaborate-to-bring-isoflex-to-european-markets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fmc-bayer-collaborate-to-bring-isoflex-to-european-markets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0385154629.USD","BK4007","BK4545","BK4588","BAYRY","BK4093","FMC","BK4585","LU0471298777.SGD"],"gpt_icon":0},{"id":"2523075615","title":"Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2523075615","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523075615?lang=en_us&edition=fundamental","pubTime":"2025-03-28 21:45","pubTimestamp":1743169500,"startTime":"0","endTime":"0","summary":"Kodiak SciencesKOD reported a loss of 84 cents per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 90 cents. The company had incurred a loss of $1.13 per share in the year-ago quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The company currently does not have any approved products in its portfolio. As a result, it has yet to generate revenues.Research and development expenses were $31.8 million in the reported quarter, down 32% year over year. The decrease was mainly due to reduced manufacturing activities and forfeitures of equity awards, partially offset by clinical activities from active studies.General and administrative expenses were $14.4 million, down 14% year over year, primarily due to lower non-cash stock-based compensation expenses.Kodiak is also enrolling patients in the phase Ib APEX study, which will evaluate its third investigational candidate, KSI-101, in two new cohorts — cohort 1 in patients w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kodiak-q4-loss-narrower-expected-134500496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DVAX","LU2360106780.USD","BK4139","BK4534","LU1852331112.SGD","LU2250418816.HKD","BK4554","BK4605","IE00BMPRXR70.SGD","LU1951200564.SGD","BAYRY","LU0823421416.USD","LU1242518857.USD","LU0823434583.USD","BK4529","LU0823421333.USD","LU0081259029.USD","LU1064131342.USD","CORT","BK4543","BK4007","BK4532","LU1803068979.SGD","IE00B5949003.HKD","LU1989764664.SGD","LU0979878070.USD","BK4573","BK4141","IE0009356076.USD","IE0004445239.USD","LU1880398554.USD","LU1303367103.USD","BK4588","LU0823434740.USD","LU0127658192.USD","BK4585","LU1951198990.SGD","LU2098885051.SGD","LU0642271901.SGD","LU2458330169.SGD","LU1880398471.USD","KOD","LU1988902786.USD","LU1559883803.SGD","LU0082616367.USD","LU2458330243.SGD","BK4512","BK4505","LU2054465674.USD"],"gpt_icon":1},{"id":"2522537272","title":"FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537272","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537272?lang=en_us&edition=fundamental","pubTime":"2025-03-28 03:00","pubTimestamp":1743102000,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx .The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors .Simultaneously, the drug was approved for adult and pediatric patients  with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET .Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status.The approval came ahead of the target action date of April 3, 2025.The company is now focused on developing zanzalintinib, a next-generation oral TKI. In January 2025, results from an expansion cohort of the phase Ib/II STELLAR-001 study ev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-expands-exelixis-cabometyx-label-190000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0306806265.USD","RCC","LU0096364046.USD","BK4139","BK4534","LU1093756168.USD","LU0321505439.SGD","LU1989771016.USD","BAYRY","LU0154236417.USD","BMY","LU0321505868.SGD","IE0002141913.USD","LU0985481810.HKD","IE00B2B36J28.USD","LU1323610961.USD","LU1670710661.SGD","LU1868836914.USD","LU1718418525.SGD","LU0225284248.USD","LU1670710588.SGD","IE00BZ1G4Q59.USD","LU2360032135.SGD","BK4559","DTC","LU1032466523.USD","IE00BSNM7G36.USD","LU2242646821.SGD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU1868836757.USD","LU0456855351.SGD","LU0456854461.SGD","CRC","IE00BFXG1179.USD","LU1585245621.USD","IE00BKVL7J92.USD","BK4588","LU0266512127.USD","LU2125154935.USD","LU0237698245.USD","LU1261432733.SGD","LU0882574055.USD","EXEL","LU1868837300.USD","LU1093756325.SGD","LU1074936037.SGD","LU2133065610.SGD"],"gpt_icon":1},{"id":"2522003463","title":"SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522003463","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522003463?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:46","pubTimestamp":1743079560,"startTime":"0","endTime":"0","summary":"Shares of Soleno TherapeuticsSLNO have rallied 37% in the premarket hours today following the FDA approval of Vykat XR extended-release tablets for treating hyperphagia in adults and children aged four years and older with Prader-Willi syndrome . The company expects to launch the drug in the United States in April 2025.Soleno’s Vykat XR, previously referred to as DCCR, is an innovative, once-daily, proprietary extended-release dosage form that contains diazoxide choline, the crystalline salt form of diazoxide. Although not approved for treating PWS, the parent molecule, diazoxide, treats a few rare diseases in neonates, infants, children and adults.Per the PWS Association USA, approximately one in every 15,000 newborns suffers from this rare genetic disorder. The most common symptom of PWS is hyperphagia, an abnormally increased appetite for food, often leading to excessive eating, which takes a serious toll on the quality of life of patients suffering from it. In the long term, hyperp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/slno-stock-rallies-fda-approval-124600150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171402.SGD","ACAD","BAYRY","LU2065171311.SGD","PWS","BK4532","LU0566484027.USD","LU2065170008.USD","SLNO","CORT","LU2065169927.USD","BK4139","LU1559883803.SGD","BK4007"],"gpt_icon":0},{"id":"2522344273","title":"Elliott gauged investor interest in Bayer’s consumer health business, FT says","url":"https://stock-news.laohu8.com/highlight/detail?id=2522344273","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522344273?lang=en_us&edition=fundamental","pubTime":"2025-03-27 02:40","pubTimestamp":1743014410,"startTime":"0","endTime":"0","summary":"Elliott Management held talks with private equity groups in recent months to gauge interest in buying Bayer’s (BAYRY) consumer health business, as ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/elliott-gauged-investor-interest-in-bayers-consumer-health-business-ft-says?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/elliott-gauged-investor-interest-in-bayers-consumer-health-business-ft-says?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","FT","BK4007"],"gpt_icon":0},{"id":"2521658779","title":"Is Bayer (BAYRY) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521658779","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521658779?lang=en_us&edition=fundamental","pubTime":"2025-03-24 21:40","pubTimestamp":1742823609,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Bayer Aktiengesellschaft  been one of those stocks this year?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bayer Aktiengesellschaft is one of 1011 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Bayer Aktiengesellschaft is currently sporting a Zacks Rank of #2 .In Enhabit's case, the consensus EPS est","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bayer-bayry-stock-outpacing-medical-134009618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EHAB","BAYRY","BK4007","BK4196"],"gpt_icon":0},{"id":"2521721912","title":"Nvidia, Palantir, Tesla, MicroStrategy, Bayer, James Hardie, AZEK: Stocks to watch today","url":"https://stock-news.laohu8.com/highlight/detail?id=2521721912","media":"Quartz","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521721912?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:36","pubTimestamp":1742819791,"startTime":"0","endTime":"0","summary":"Stocks may open higher today as futures tied to the S&P 500, the Nasdaq 100, and the Dow Jones Industrial Average all gained following reports that the Trump administration may take a more-targeted approach than initially planned on tariffs it’s set to roll out on April 2.The White House will probably omit industry-specific tariffs but apply reciprocal levies on nations that account for the bulk of trade with the U.S., the Wall Street Journal  said, citing an unidentified Trump administration official.With investors uncertain about what will materialize from Donald Trump’s plans — especially over trade — economic indicators are set to be in focus this week.On Monday, the preliminary purchasing manager index  numbers for March will probably whow economic deterioration. The manufacturing reading may have dropped to 52.2 from 52.7, and the services level to 50.1 from 51, according to the StreetAccount survey. A number above 50 indicates expansion. The data are due at 9:45 a.m. EDT.The Sho","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvidia-palantir-tesla-microstrategy-bayer-123631063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["3NVD.UK","LU0061474960.USD","NVDU","IE00BQXX3C00.GBP","LU0708994859.HKD","LU0353189763.USD","NVD","MSTR","BK4613","NVDA","BK4531","NVDY","NVD3.UK","PLTR","STRK","IE00B19Z8X17.USD","LU0965509010.AUD","JHX","NVDX","NVIW.SI","NWSA","TSLA","BK4555","SNVD.UK","LU2125909247.SGD","AZEK","TSYW.SI","BK4550","IE0004445239.USD","LU1064131342.USD","HK0000320264.USD","NVDS","SGXZ99366536.SGD","NVDD","LU1066053197.SGD","LU0096364046.USD","LU0823434740.USD","LU1868836757.USD","NVD2.UK","NVDS.UK","2NVD.UK","BAYRY","SGXZ51526630.SGD","TSLL","LU0985320562.USD"],"gpt_icon":1},{"id":"2521971808","title":"Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521971808","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521971808?lang=en_us&edition=fundamental","pubTime":"2025-03-24 17:22","pubTimestamp":1742808120,"startTime":"0","endTime":"0","summary":"Bayer shares fell sharply after the company was ordered to pay $2.1 billion by a jury in a Georgia state court, the latest legal defeat for the company in a case about its Roundup weedkiller.The German agricultural and pharmaceutical group said the jury in a trial in the State Court of Cobb County, Georgia, on Friday reached a verdict in favor of the plaintiff. The verdict includes $2 billion in punitive damages and $65 million in compensatory damages, the company said.Shares in Bayer were down 6.6% at 22.48 euros in European morning trade Monday, having fallen as much as 8.8% earlier. The stock is up about 16% since the start of the year, amid a rally in German shares.\"We disagree with the jury's verdict, as it conflicts with the overwhelming weight of scientific evidence and the consensus of regulatory bodies and their scientific assessments worldwide,\" Bayer said. \"We believe that we have strong arguments on appeal to get this verdict overturned and the excessive and unconstitutiona","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2521714287","title":"8 key drug patents expiring soon — and what it means for the market","url":"https://stock-news.laohu8.com/highlight/detail?id=2521714287","media":"Quartz","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521714287?lang=en_us&edition=fundamental","pubTime":"2025-03-24 17:00","pubTimestamp":1742806800,"startTime":"0","endTime":"0","summary":"In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. - Image: Mario Tama / Staff . Nothing drives down a drug’s price like competition. According the U.S. Food and Drug Administration , a drug’s wholesale price drops by an average of 39% after just one generic competitor enters the market. With four generic competitors, prices tumble by 79%. These reductions translate into billions of dollars in savings for American consumers.But before generics can hit the market, a drug’s patent must first expire. In the United States, drug patents last for 20 years from the date a patent application is filed, giving the pharmaceutical company that holds the patent the ability to set the drug’s price without competition during this time.Here are some key drug patents expiring soon.Bristol Myers Squibb and Ono Pharmaceutical’s Opdivo, a treatment for melanoma and other cancers, generated $9;3 billion in global sales. In","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/8-key-drug-patents-expiring-090000809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BAYRY","LU2023250843.SGD","BK4581","LU0471298777.SGD","SG9999014906.USD","LU1989771016.USD","BK4592","LU2592432038.USD","LU0208291251.USD","SGXZ57979304.SGD","LU2505996681.GBP","NVO","PFE","LU1914381329.SGD","SG9999014575.USD","GB00BDT5M118.USD","MRK","IE00BK4W5L77.USD","LU0943347566.SGD","LU1127390331.HKD","LU0466842654.USD","LU1551013425.SGD","AZN","BMY","IE00BK4W5M84.HKD","LU1974910355.USD","JNJ","LU2265009873.SGD","LU1032466523.USD","LU0114720955.EUR","LU1506573853.SGD","IE0009355771.USD","LU2023250504.SGD","LU0820561818.USD","IE00BLSP4239.USD","LU1720051017.SGD","LU0689472784.USD","LU2491050154.USD","LLY","IE00BDGV0183.EUR","LU2242652126.USD","LU0795875169.SGD","LU0109391861.USD","LU2461242641.AUD","LU0345770993.USD","LU1670710588.SGD","LU0256863811.USD","IE00B4R5TH58.HKD","LU1941712264.USD","LU0306807586.USD"],"gpt_icon":1},{"id":"2521776482","title":"Bayer Ordered to Pay $2.1 Billion After Losing Roundup Weedkiller Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2521776482","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521776482?lang=en_us&edition=fundamental","pubTime":"2025-03-24 15:22","pubTimestamp":1742800920,"startTime":"0","endTime":"0","summary":"Bayer said it was ordered to pay $2.1 billion in a case about its Roundup weedkiller after a jury in a Georgia state court reached a verdict in favor of the plaintiff.The German agricultural and pharmaceutical group said the verdict from the jury Friday in a trial in the State Court of Cobb County, Georgia, includes $2 billion in punitive damages and $65 million in compensatory damages.\"We disagree with the jury's verdict, as it conflicts with the overwhelming weight of scientific evidence and the consensus of regulatory bodies and their scientific assessments worldwide,\" Bayer said. \"We believe that we have strong arguments on appeal to get this verdict overturned and the excessive and unconstitutional damage awards eliminated or reduced.\". The decision marks the latest legal setback for a company that has been for years fighting lawsuits stemming from its $63 billion acquisition of Monsanto, which developed Roundup. Critics have argued that glyphosate, the active ingredient found in ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Bayer Ordered to Pay $2.1 Billion After Losing Roundup Weedkiller Case","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":65,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"date":"2025-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-13","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"","actualEps":null},{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"date":"2024-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722974400000,"name":null,"time":"Post Market","dateTimestamp":1722916800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2016-04-27","recordDate":"2016-04-29","paymentDate":"2016-05-12","value":2.091196,"currency":"USD"},{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"},{"executeDate":"2022-05-02","recordDate":"2022-05-03","paymentDate":"2022-05-16","value":0.549114,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":2,"updateTime":1746244800000}}}